Key points from article :
Five patients with mild to moderate dementia received a proprietary intranasal dual gene therapy.
Treatment demonstrated an excellent safety profile with no complications.
Efficacy data was also collected and tracked, including cognitive testing, immune system response.
Systemic telomere lengthening was observed in all patients.
Longer telomeres linked with reduced risk for myriad of age-related diseases and all-cause mortality.
Telomere lengthening leads to longer replicative cell life and is associated with a younger biological age.
Patrick Sewell, BioViva's Director of Clinical Affairs says "... patient's score on the Folstein test declines approximately 3-points-per-year after diagnosis".
BioViva CEO Elizabeth Parrish stated, "... Anyone who has lost a loved one to dementia understands the importance of this work."
The patent-pending study was sponsored by Maximum Life Foundation.
Research by Integrated health systems published in Journal of Regenerative biology and Medicine.
